Mohamad Sarmini

Dr. Mohamad Sarmini

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, L-1526, Luxembourg
+1

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Pharmacological Research
Verified
Journal Article
Closed access
GLGiovanni Lavorgna
Giovanni Lavorgna
Riccardo VagoRiccardo Vago
Riccardo Vago
MSMohamad Sarmini
Mohamad Sarmini
FMFrancesco Montorsi
Francesco Montorsi
ASAndrea Salonia
Andrea Salonia
MBMatteo Bellone
Matteo Bellone

10 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SFSabrina Fritah
Sabrina Fritah
AMArnaud Muller
Arnaud Muller
WJWei Jiang
Wei Jiang
RMRamkrishna Mitra
Ramkrishna Mitra
MSMohamad Sarmini
Mohamad Sarmini
SNSimone Niclou
Simone Niclou
Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.